NCT07171593Enrolling by invitation
High-protein Oral Nutrition With HMB for Active CD Patients With Sarcopenia
Efficacy of High-protein Oral Enteral Nutrition Supplement Supplemented With HMB in Active Crohn's Disease With Sarcopenia: a Prospective, Randomized, Controlled Study
Source: ClinicalTrials.gov · Last updated 12 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The efficacy of B-hydroxy-β-methybutyrate in sarcopenia
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 10 Apr 2025
- Start date
- 4 Mar 2024
- Primary completion date
- 22 May 2024
- Lead sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Diseases
- Crohn's disease
- NCT number
- NCT07171593
What you commit to
- Study type: Interventional
- Planned participants: 44
- From 4 Mar 2024 to the primary completion date, 22 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Underwent CD-related intestinal surgery or received biologic therapy within the past month, or received immunosuppressive/antibiotic therapy related to CD within 2 weeks prior to enrollment.
Other illness
- Short bowel syndrome;
- High-output jejunal fistula;
- Complete mechanical intestinal obstruction, acute gastrointestinal bleeding, or severe intra-abdominal infection;
- Severe hepatic, renal, or cardiac diseases, or malignant tumors;
- History of allergy or contraindication to Ensure or HMB;
- Congenital disorders of sugar or amino acid metabolism;
Other
- Severe stress or shock status;
- Persistent severe vomiting or intractable diarrhea;
Who the study is looking for
- Patients with active Crohn's disease (CD) who visited the Sixth Affiliated Hospital of Sun Yat-sen University between July 2023 and December 2024;
- Aged 18-50 years;
- Complicated with sarcopenia;
- Willing and able to tolerate oral exclusive enteral nutrition (EEN) therapy;
- Signed informed consent and able to comply with the study procedures;
- Colonic or ileocolonic type CD (SES-CD ≥6; if only terminal ileum is involved, SES-CD ≥4).
Age in the registry: 18 years to 50 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sixth Hospital Affiliated to Sun Yat-sen University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.